Twenty-two women with unexplained heavy menstrual blood loss (average loss for two cycles of >80 ml) were treated with the prostaglandin synthetase inhibitor menfenamic acid during two consecutive menstruations. There was a significant reduction in menstrual blood loss on mefenamic acid therapy, the median loss being 137 ml before treatment and 76 ml while on treatment. Reduction in menstrual loss was achieved in 20 of the 22 patients but varied from a 2% to 78% reduction. The greater the menstrual loss before treatment, the more it was reduced on mefenamic acid therapy. Endometrial concentrations of prostaglandins E2 and F2 alpha in the follicular phase of the cycle were similar whether or not patients had menorrhagia. In the luteal phase, however, 6 of 14 patients with menorrhagia had higher endometrial prostaglandin E2 and F2 alpha concentrations than all 13 controls.

Adolescent↗

PubMedDate not supplied

Effects of antibodies to estradiol-17beta and to progesterone on the placental weight and pregnancy in rats--a quantitative study.

Explore the source record for details and available documents.

Animals↗

PubMedDate not supplied

Chromatographic identification of Met- and Leu-enkephalin in the human fetal spinal cord.

Using the indirect immunofluorescence method, enkephalin-like immunoreactivity was visualized on human fetus spinal cord sections (gestational age from 17 to 25 weeks). Immunolabeled varicose fibers and terminal-like structures were seen through the whole length fetal spinal cord principally in the dorsal gray, in the intermediate gray and in the lateral funiculus. A few enkephalin-like immunoreactive cells were sometimes detected in the intermediate gray. Finally, some immunolabeled fibers were also visible in the ventral spinal cord especially proximate to the motor nuclei areas at the sacral level. Fetal spinal cord tissue extracts from the cervical thoracic and lumbosacral region were chromatographically analyzed using high pressure liquid chromatography in combination with the radioimmunoassay. This biochemical analysis indicates that authentic pentapeptides Met- and Leu-enkephalin may account for a large part (more than 90%) of the enkephalin-like immunoreactivity detected in the fetal spinal cord investigated. Taken together our results suggest that the biosynthetic processing of Met- and Leu-enkephalin in this tissue might be functional early before birth.

Chromatography, High Pressure Liquid↗

PubMedDate not supplied

Basal and PAF-, interleukin 1-, ether stress-induced hypothalamic pituitary adrenal secretion of conscious rat: modulation by PAF antagonists.

We have previously shown that exogenous (1 to 5 nmol i.c.v.) PAF induces a rapid increase in plasma ACTH and beta endorphin followed by an increase in plasma corticosterone in conscious rats. The stimulatory action of PAF on the secretion of hypothalamic-pituitary-adrenal (HPA) axis products is mediated at least partly by stimulating hypothalamic CRF release. In addition rat hypothalamic membranes have two populations of specific PAF binding sites. In order to clarify the mode of PAF action on the stress-related hormones, we have now investigated the effect of two PAF antagonists, BN 50739 and RP 52770, on basal and PAF-induced ACTH and corticosterone secretion by conscious rats and on PAF specific binding to rat hypothalamic membranes. The role of PAF as a mediator of neuroendocrine secretion in response to acute stress was examined by determining the effect of PAF antagonists on ether-stress inducing HPA activity. We have also investigated their effect on IL 1-induced HPA activity. The ability of BN 50739 and RP 52770 to displace 3H PAF from its hypothalamic binding sites was correlated with their ability to alter basal hormone secretion and to counteract the PAF-stimulated secretion of HPA axis hormones in vivo (P less than 0.05 by ANOVA). Pretreatment with BN 50739. (50 nmol i.c.v.) did not alter ACTH response to a 1 min ether exposure or to IL1 beta injection (2 nmol i.c.v.). In contrast, RP 52770 (55 nmol i.c.v.) significantly inhibited the ether stress-induced ACTH and corticosterone production by 50% (P less than 0.05). In parallel, pretreatment with RP 52770 (55 nmol i.c.v.) caused a significant inhibition of IL1 beta-induced ACTH secretion. These results suggest that PAF acts, in vivo, on ACTH and corticosterone secretion, through a centrally mediated CRF dependent mechanism involving PAF receptor sites. Additionally, the data also indicate that PAF could have a central role in mediating basal and stress-induced ACTH secretion and that IL 1-induced HPA secretion may be mediated at least in part through the production of PAF.

Adrenocorticotropic Hormone↗

PubMedDate not supplied

A competitive receptor binding assay for platelet-activating factor (PAF): quantification of PAF in rat brain.

A radioreceptor assay (RRA) was developed using rabbit platelet membrane preparations to quantify platelet-activating factor (PAF) and lyso-PAF, the deacylated derivative of PAF, in a variety of tissues and biological fluids. We examined PAF and lyso-PAF levels in different rat brain areas with regard to the many proven and postulated actions of PAF in brain functions. Human saliva was selected to check the validity of this RRA. The samples were extracted with methanol/chloroform/water and purified by high-performance liquid chromatography on a 5-microns Nucleosil Si column (overall recovery: 78%). Sample extracts were acetylated before chromatography to assay lyso-PAF. PAF itself was assayed in non-aceylated samples. A competitive binding assay was performed using aliquots of platelet membrane preparation and tritiated PAF. The minimum detectable amount of PAF was 144 pg per tube and the receptor was highly specific for PAF. In human saliva, we confirm the presence of PAF and lyso-PAF within the range expected. Moreover there was a good correlation between the RRA and the aggregation assay (r = 0.976). A defined cocktail of protease inhibitors allowed storage of platelet membrane preparations for at least 3 months at -20 degrees C with no change in binding properties. In the brain we observed the prevalent presence of lyso-PAF and large variations in PAF and lyso-PAF concentrations between the different brain areas analyzed. PAF was undetectable in the hypothalamus but the lyso-PAF concentration was 2.5 micrograms/g wet tissue. The PAF concentration in the cortex varied from 0 to 16 ng/g wet tissue while that of lyso-PAF was 0.7 micrograms/g wet tissue. Moreover the amount of lyso-PAF varied between the different brain areas analyzed. The hippocampus contained the highest amount (7 micrograms/g wet tissue), and relatively high levels were found in the hypothalamus, medulla oblongata and corpus striatum. The cerebellum and cortex contained the lowest levels of lyso-PAF. These findings show that PAF is present in the central nervous system mainly in its inactive form, lyso-PAF, and suggest that its effects as a modulator of brain function may be dependent on deacetylation, rather than synthesis.

Animals↗

PubMedDate not supplied

Viroimmunoenzymoassay for detection of anti-penicilloyl antibodies and penicilloyl residues: comparison of results obtained by radio-, viro- and enzymoimmunoassay.

A new technic named viroimmunoenzymoassay is described. The principle is the same as the classical viroimmunoassay which uses as tracer a bacteriophage bound covalently to an hapten. Immuno-specific neutralization of these modified bacteriophages by an hapten antiserum allows to detect and to test hapten antibodies or the haptens with a great sensitivity. In the new technic the visualization of the bacterial lysis is estimated by measure of the amount of beta-galactosidase which is released into the medium by Escherichia coli BB bacteria. These are previously induced by isopropyl thiogalactoside or lactose. The method is applied to the assay of penicilloyl groups bound covalently with another molecule, and its performances are compared with three other classical immunological methods: the radio-, enzymo- and viroimmunoassay.

Animals↗